List view / Grid view
21 October 2015 | By Victoria White
The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis did not achieve its primary and secondary endpoints...
7 October 2015 | By Victoria White
Biogen is to present the data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)...
25 September 2015 | By Victoria White
Elocta is a recombinant factor VIII Fc fusion protein product that, if approved, would be the first haemophilia A treatment with prolonged circulation available in the EU...
11 September 2015 | By Victoria White
Biogen is assessing the potential of MT-1303 in multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and other autoimmune indications...
8 September 2015 | By Victoria White
Biogen's Phase 3 programme includes two global studies designed to evaluate the efficacy and safety of aducanumab in slowing cognitive impairment and the progression of disability in people with early Alzheimer’s disease...
18 August 2015 | By Victoria White
Interim results from the B-YOND study support the long-term safety and efficacy of Alprolix in people with severe haemophilia B treated for up to two years...
22 July 2015 | By Victoria White
Biogen has announced new results from an interim analysis of the Phase 1b PRIME study of aducanumab in patients with prodromal or mild Alzheimer’s disease...
26 June 2015 | By Victoria White
Biogen and SOBI have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) for Alprolix...
19 May 2015 | By Victoria White
Biogen UK has been named as one of the UK’s best workplaces in the Medium Category in the ‘Great Place to Work®’ annual Best Workplaces list...
31 March 2015 | By Victoria White
Biogen and AbbVie have announced that the EMA has validated the companies’ MAA for Zinbryta for the treatment of relapsing forms of MS in the EU...
23 March 2015 | By Victoria White
Biogen Idec has announced data from the Phase 1b study of aducanumab, in which the drug demonstrated positive results in patients with prodromal or mild AD...
19 November 2014 | By GlobalData
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to research and consulting firm GlobalData...
19 November 2014 | By Forward Pharma A/S
Forward Pharma A/S announced that it has filed a lawsuit against Biogen Idec GmbH, Biogen Idec International GmbH and Biogen Idec Ltd. in the Regional Court in Dusseldorf, alleging infringement of its German utility model DE 20 2005 022 112 due to Biogen Idec's marketing of Tecfidera® in Germany...
19 September 2014 | By BIogen Idec
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY™ (peginterferon beta-1a) were maintained in adults with relapsing-remitting multiple sclerosis (RRMS) beyond the first year of the study...
18 September 2014 | By Biogen Idec
Biogen Idec and AbbVie announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity...
